tiprankstipranks
Advertisement
Advertisement

GANX Stock Latest News

Gain Therapeutics Extends Cash Runway Into 2027 Operations
Company AnnouncementsGain Therapeutics Extends Cash Runway Into 2027 Operations
16d ago
8K
GANX
Gain Therapeutics: Buy Rating Reaffirmed on GT-02287 Clinical Momentum and Differentiated GCase Strategy; $7 Price Target Unchanged
PremiumRatings
Gain Therapeutics: Buy Rating Reaffirmed on GT-02287 Clinical Momentum and Differentiated GCase Strategy; $7 Price Target Unchanged
1M ago
GANX
Gain Therapeutics Buy Rating Reiterated as FDA Clears GT-02287 Phase 2; 12-Month $8 Price Target Maintained
PremiumRatings
Gain Therapeutics Buy Rating Reiterated as FDA Clears GT-02287 Phase 2; 12-Month $8 Price Target Maintained
1M ago
GANX
Closing Bell Movers: AeroVironment jumps after quarterly report
PremiumThe Fly
Closing Bell Movers: AeroVironment jumps after quarterly report
1M ago
TW
AVAV
Gain Therapeutics advances GT-02287 into Phase 2 Parkinson’s trial
PremiumCompany Announcements
Gain Therapeutics advances GT-02287 into Phase 2 Parkinson’s trial
1M ago
8K
GANX
Gain Therapeutics receives FDA clearance of GT-02287 IND application
PremiumThe FlyGain Therapeutics receives FDA clearance of GT-02287 IND application
1M ago
GANX
Gain Therapeutics Shareholders Confirm Board and Auditor Choices
Premium
Company Announcements
Gain Therapeutics Shareholders Confirm Board and Auditor Choices
1M ago
8K
GANX
Shrader Reiterates Buy on GANX as Parkinson’s Data Strengthens GT-02287 Profile; $5 Price Target Maintained
Premium
Ratings
Shrader Reiterates Buy on GANX as Parkinson’s Data Strengthens GT-02287 Profile; $5 Price Target Maintained
2M ago
GANX
Gain Therapeutics presents data from Phase 1b study of GT-02287
PremiumThe Fly
Gain Therapeutics presents data from Phase 1b study of GT-02287
2M ago
GANX
Gain Therapeutics Reports Interim Data for Parkinson’s Candidate
PremiumCompany Announcements
Gain Therapeutics Reports Interim Data for Parkinson’s Candidate
2M ago
8K
GANX
Is GANX a Buy, Before Earnings?
PremiumPre-Earnings
Is GANX a Buy, Before Earnings?
3M ago
GANX
Buy Rating Reaffirmed on Encouraging GT-02287 Parkinson’s Data and Upcoming Catalysts; 12‑Month Price Target Maintained at $7
PremiumRatings
Buy Rating Reaffirmed on Encouraging GT-02287 Parkinson’s Data and Upcoming Catalysts; 12‑Month Price Target Maintained at $7
3M ago
GANX
Gain Therapeutics price target lowered to $8 from $10 at Roth Capital
PremiumThe FlyGain Therapeutics price target lowered to $8 from $10 at Roth Capital
3M ago
GANX
Gain Therapeutics reports Q1 EPS (13c), consensus (14c)
Premium
The Fly
Gain Therapeutics reports Q1 EPS (13c), consensus (14c)
3M ago
GANX
Gain Therapeutics management to meet with Maxim
Premium
The Fly
Gain Therapeutics management to meet with Maxim
4M ago
GANX
Reiterating Buy on Gain Therapeutics: Promising GT-02287 Parkinson’s Data and Diversified GCase Pipeline Support $8 Target
PremiumRatings
Reiterating Buy on Gain Therapeutics: Promising GT-02287 Parkinson’s Data and Diversified GCase Pipeline Support $8 Target
4M ago
GANX
Gain Therapeutics reports Q4 EPS (61c), consensus (14c)
PremiumThe Fly
Gain Therapeutics reports Q4 EPS (61c), consensus (14c)
4M ago
GANX
Gain Therapeutics Reports Promising GT-02287 Parkinson’s Data
PremiumCompany Announcements
Gain Therapeutics Reports Promising GT-02287 Parkinson’s Data
5M ago
8K
GANX
Gain announces presentations on Phase 1b clinical study of GT-02287
PremiumThe Fly
Gain announces presentations on Phase 1b clinical study of GT-02287
5M ago
GANX
Gain Therapeutics, Inc. (GANX) Q4 Earnings Cheat Sheet
PremiumPre-EarningsGain Therapeutics, Inc. (GANX) Q4 Earnings Cheat Sheet
5M ago
GANX
Gain Therapeutics provides regulatory update on GT-02287
Premium
The Fly
Gain Therapeutics provides regulatory update on GT-02287
5M ago
GANX
Buy Rating on Gain Therapeutics Driven by Validated Mechanism, Compelling Phase 1b Parkinson’s Data, and Attractive Risk‑Reward Despite Near‑Term Financing Needs
Premium
Ratings
Buy Rating on Gain Therapeutics Driven by Validated Mechanism, Compelling Phase 1b Parkinson’s Data, and Attractive Risk‑Reward Despite Near‑Term Financing Needs
7M ago
GANX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >